A Lancet review covers emerging antihypertensive therapies including siRNA agents, endothelin receptor antagonists, and GLP-1 RAs that target novel physiological pathways.
Novel pathways targetedsiRNA, endothelin, and GLP-1-based approaches expand the antihypertensive toolkit
What the researchers found
Next-generation antihypertensives targeting novel pathways — including siRNA, endothelin antagonists, and GLP-1 RAs — show promise for improving global blood pressure control.
Why it matters
Hypertension is the world's leading modifiable cardiovascular risk factor, yet control rates remain unacceptably low. Novel drug classes could improve outcomes for millions.
How the study worked
Narrative review in The Lancet of emerging antihypertensive drug classes and their clinical evidence.
What this study cannot tell us
Lancet review — comprehensive but most novel agents are in clinical trials without definitive long-term outcome data.
How to read the evidence
Lancet review — authoritative synthesis in a top-tier journal, covering agents at various stages of clinical development.
When this study was published
Published 2026 in The Lancet.
The bigger picture
The hypertension treatment landscape is about to undergo its most significant expansion in decades, with RNA-based therapies potentially offering long-acting, adherence-friendly options.
Questions still open
- Will RNA-based antihypertensives improve adherence through less frequent dosing?
- How will GLP-1 RAs be integrated into hypertension treatment algorithms?
Common questions
Why are new blood pressure drugs needed?
What are RNA-based blood pressure drugs?
Read the original research
New drug therapies for hypertension.
Lancet (London, England)
Citation
Azizi, Michel; Tuttle, Katherine R; Brown, Jenifer M; Piskorz, Daniel L; Kario, Kazuomi; Williams, Bryan. (2026). New drug therapies for hypertension.. Lancet (London, England). https://doi.org/10.1016/S0140-6736(25)02064-1